Call Us for Patient Support (888) 708-5660

Phase I Study for Innovative Mesothelioma Treatment Seeking Participants

Memorial Sloan Kettering Cancer Center (MSK) is currently recruiting mesothelioma patients for a phase I study aimed at helping develop new treatment options for this often-fatal disease. The study involves a treatment that utilizes a patient’s own T cells and genetically modifying them in the laboratory to recognize mesothelin. The modified T cells, known as CAR T cells, are then returned to the patient to find and kill cancerous cells throughout the body. This approach is a form of immunotherapy.

According to MSK, “researchers have observed that the protein mesothelin is overexpressed in pleural disease from mesothelioma and lung or breast cancers. In this study, researchers are seeking to find the highest dose of genetically modified T cells (a type of white blood cell) that can be used to treat patients with pleural cancers that have continued to grow despite standard therapy.” All treatments in the study will be given directly into the chest cavity (intrapleurally) via a thin flexible tube called catheter.

To be eligible for the study, patients must be 18 years of age or older, they must have mesothelioma, or breast or non-small cell lung cancer that has spread to the pleura, and has continued to grow despite prior therapy, and the patients’ tumors must contain the mesothelin protein. In addition, four weeks must have passed since any major surgery or completion of prior chemotherapy or radiation therapy and entry into the study.

MSKCC released the call for participants with the headline A Phase I Study of Immunotherapy with Genetically Engineered T Cells (CAR T Cells) to Treat Mesothelioma and Malignant Pleural Disease from Lung and Breast Cancers. The full title of the study is A Phase I Clinical Trial of Malignant Pleural Disease Treated with Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen Mesothelin.

Study locations include Memorial Sloan Kettering Memorial Hospital, Memorial Sloan Kettering Commack, Memorial Sloan Kettering Basking Ridge, Memorial Sloan Kettering Rockville Centre, Memorial Sloan Kettering Westchester, and Memorial Sloan Kettering Monmouth.

If you have been diagnosed with mesothelioma, ask your doctor about currently recruiting trials such as the MSK study. Innovative clinical trials such as this could help treat your specific type of mesothelioma. Talk to your doctor today.

 

Sources

"A Phase I Study of Immunotherapy with Genetically Engineered T Cells." Memorial Sloan Kettering Cancer Center (MSK). Gerstner Sloan Kettering Graduate School of Biomedical Sciences, 26 Oct. 2017. Web. 30 Nov. 2017.

"Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen Mesothelin." ClinicalTrials.gov. U.S. National Library of Medicine, 26 Oct. 2017. Web. 30 Nov. 2017.